Download or read book Improvement in survival outcomes of triple sequential targeted therapy in patients with metastatic renal cell carcinoma written by Jérémy Msika and published by . This book was released on 2019 with total page 70 pages. Available in PDF, EPUB and Kindle. Book excerpt: Objectif: Depuis la multiplication des thérapies ciblées, elles ont été utilisées pour différentes lignes et dans différentes séquences dans le traitement du cancer du rein métastatique. Le choix est en fonction des disponibilités et des recommandations mais la séquence de traitement optimale reste inconnue. Cette étude compare les résultats de survie des patients atteints d'un cancer du rein métastatique traités par l'utilisation séquentielle d'au moins trois thérapies ciblées en débutant par le sunitinib. Méthodes: De janvier 2005 à mars 2017, les patients atteints d'un cancer du rein métastatique traités par au moins trois thérapies ciblées avec le sunitinib en première ligne ont été étudiés rétrospectivement. Seuls les patients traités par sunitinib puis au moins deux autres lignes successives ont été inclus. Tous les patients ont reçu le traitement de deuxième et troisième lignes après progression tumorale. La survie sans progression et la survie globale ont été estimées et les séquences thérapeutiques ont été comparées. Résultats: 273 patients atteints d'un cancer du rein métastatique ont été traités par sunitinib en première ligne. Au total, 84 patients (30%) ont été traités avec au moins trois lignes de thérapies ciblées et ont été inclus dans l'étude. Aucune différence significative n'a été constatée entre les séquences sur la survie sans progression. La survie globale était plus longue chez les patients recevant everolimus en seconde ligne suivi d'axitinib en comparaison à la séquence inverse avec une différence statistiquement significative (39,1 versus 25,9 mois, p = 0,0154). Conclusion: Peu de patients ont reçu trois lignes de thérapie ciblée. La séquence VEGFR - mTORi - VEGFR était associée à une survie améliorée par rapport à VEGFR - VEGFR - mTORi. MSKCC, Heng et la résistance primaire à la première ligne étaient des facteurs pronostiques.
Download or read book Integrating Multidisciplinary Treatment for Advanced Renal Cell Carcinoma written by Rana R. McKay and published by Springer Nature. This book was released on 2023-12-03 with total page 418 pages. Available in PDF, EPUB and Kindle. Book excerpt: The field of kidney cancer has dramatically evolved over the past several years due to notable advances. Most importantly, systemic treatment options have expanded to include combination regimens for advanced disease and expansion of treatment options in the adjuvant setting. Additionally, surgical management has evolved towards nephron-sparing and minimally invasive approaches for treatment of localized disease; the role of surgery and focal therapy are changing for patients with advanced disease. While kidney cancer is a common malignancy in both men and women worldwide, mortality has improved over time given advancements in modern oncology. This book provides a comprehensive, state-of-the art review of the field, and serves as a valuable resource for clinicians, surgeons and researchers with an interest in kidney cancer. The book reviews new data about systemic treatment options for patients with advanced disease including strategies in the treatment naïve and post frontline setting. It covers new data regarding perioperative and adjuvant treatments for patients with localized disease and will highlight novel targets and treatments under development. Integration of surgery and systemic therapy through cytoreductive and consolidative approaches has yielded provocative data that promises to further advance the field, and major advances in this domain will also be discussed. Additionally, the book discusses the evolving role of alternative focal approaches including radiation therapy for patients with advanced disease. This text serves as a very useful resource for physicians and researchers dealing with and interested in this challenging malignancy. Specifically, urologists, medical oncologists, radiation oncologists, basic science and translational researchers with interest in RCC, fellows in urologic oncology, upper level residents training in urology and medical oncology, and pharmaceutical partners interested in RCC will benefit most significantly. Integrating Multidisciplinary Treatment for Advanced Renal Cell Carcinoma will provide a concise yet comprehensive summary of strategies for sequencing therapies that will help guide patient care and stimulate investigative efforts.
Download or read book Renal Cell Carcinoma written by Nizar M. Tannir and published by Oxford University Press. This book was released on 2014-10-08 with total page 211 pages. Available in PDF, EPUB and Kindle. Book excerpt: While patients with metastatic renal cell carcinoma (mRCC) are now living longer with improved quality of life, the success of novel therapies for mRCC has created challenges for practicing oncologists. Many patients who initially respond to targeted therapies ultimately develop progressive disease due to acquired resistance to these agents. Additionally, some patients do not respond at all to any of the currently approved targeted agents, underscoring the need for continued and concerted efforts to identify other relevant targets and pursue alternative therapeutic strategies. Part of the Oxford American Oncology Library, Renal Cell Carcinoma is a concise handbook that addresses the complex management of patients with mRCC. The book begins with a review of the epidemiology, pathology, and biology of renal cell carcinoma followed by chapters on specific targeted therapies and managing complications. The final chapters discuss supportive and integrative care and emerging therapies.
Download or read book Advanced and Metastatic Renal Cell Carcinoma An Issue of Urologic Clinics written by William C. Huang and published by Elsevier Health Sciences. This book was released on 2020-07-16 with total page 161 pages. Available in PDF, EPUB and Kindle. Book excerpt: The guest editors, Dr. William Huang and Dr. Ezequiel Becher, have assembled a state-of-the art issue devoted to Advanced and Metastatic Renal Cell Carcinoma (RCC). They have secured expert authors to contribute clinical reviews on the important topics involving treating and managing patients with RCC. Specific articles are devoted to the following topics: Imaging for Metastatic RCC; Adjuvant Therapy for Localized High Risk RCC; Current Standards for Therapeutic Sequencing for Advanced RCC; Role of Lymphadenectomy in patients with advanced RCC; Cytoreductive Nephrectomy in the Era of TKI/IO - Who, When and Why; Minimally Invasive Surgery for Patients with Locally Advanced and Metastatic Disease RCC; Evolving Role of Urologists in the Management of Advanced RCC; Neoadjuvant Therapy for Locally Advanced RCC; Epidemiology and Risk Assessment/Biomarkers for Patients with Advanced RCC; Radiation Therapy for Patients with Metastatic RCC; Evolving Role of Metastatectomy for Patients with Metastatic RCC; and Management of Non-Clear Cell Metastatic RCC. Readers will come away with the information they need to treat and manage patients and to improve outcomes.
Download or read book Immune checkpoint inhibitors in renal cell carcinoma written by Renate Pichler and published by Frontiers Media SA. This book was released on 2023-05-11 with total page 115 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Renal Tumor written by Jindong Chen and published by IntechOpen. This book was released on 2013-02-13 with total page 218 pages. Available in PDF, EPUB and Kindle. Book excerpt: Summarizing a decade of scientific advance and therapeutic innovation, Renal Tumor offers all physicians treating kidney cancer, as well as researchers, updated information concerning the epidemiology, biology, and treatment of renal cell carcinoma. Contributors to this book are from all over the world and are experts in their individual fields. They have provided reviews about current knowledge in the management of both localized and metastatic renal cell carcinoma, as well as the latest developments in molecular genetics, imaging, and immune dysfunction associated with the diseases. Further special attention is paid to the biology of selected target molecules and various agents that inhibit these targets, including full chapters devoted to pharmaceutical drugs that selectively inhibit receptor tyrosine kinases, such as sunitinib and axitinib. Readers such as urological physicians, researchers, and kidney cancer patients are potential beneficiaries of this book.
Download or read book Renal Cell Carcinoma written by Steven C. Campbell and published by Springer Science & Business Media. This book was released on 2012-09-25 with total page 362 pages. Available in PDF, EPUB and Kindle. Book excerpt: Renal Cell Carcinoma: Clinical Management provides a comprehensive, state-of-the art review of this field, and will serve as a valuable resource for clinicians, surgeons and researchers with an interest in kidney cancer. The volume reviews new data about risk factors for the disease, profiles the new staging system for renal cell carcinoma (RCC), highlights our current understanding of familial syndromes of RCC and their molecular genetics, and provides new perspectives about imaging of renal tumors. For localized disease, a greater appreciation of nephron-sparing approaches and the importance of preservation of renal function is discussed in detail. Advances in surgical techniques are highlighted. For metastatic disease, the molecular biology of kidney cancer is reviewed in a concise and understandable manner, including the data that has fostered novel targeted approaches that have revolutionized management. The several landmark phase III targeted therapy trials published in the last few years are placed in context with respect to current management. Integration of surgery and systemic therapy through cytoreductive and consolidative approaches has yielded provocative data that promises to further advance the field, and major advances in this domain are also be discussed.
Download or read book Renal Cell Cancer written by Jean J. M. C. H. Rosette and published by Springer Science & Business Media. This book was released on 2008-07-10 with total page 576 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book is a state-of-the-art reference work covering every aspect of the field of renal cell cancer, from diagnostics to clinical management. It provides an overview of new information concerning epidemiology, molecular and immunologic characteristics, as well as surgical therapy. Particular focus is given to the latest diagnostic tests and genetic counseling. Associated topics such as pain management and palliative care are also covered. It is a vital reference tool for urologists, oncologists and radiologists alike, being the most comprehensive volume available on the subject.
Download or read book Emerging Research and Treatments in Renal Cell Carcinoma written by Robert Amato and published by IntechOpen. This book was released on 2012-02-03 with total page 454 pages. Available in PDF, EPUB and Kindle. Book excerpt: The field of renal cell cancer has undergone a significant resurgence. This book summarizes up-to-date research and innovative ideas for the future in this rapidly changing field, which encompasses medicine, surgery, radiation oncology, basic science, pathology, radiology, and supportive care. This book is aimed at the clinician or scientist who has an interest in renal cell cancer, whether they are academic or nonacademic. The book covers tumor biology, molecular biology, surgery techniques, radiation therapy, personal testimonies, and present and future treatments of the disease that are on the horizon. The goal was to produce a textbook that would act as an authoritative source for scientists and clinicians and interpret the field for trainees in surgery, medicine, radiation oncology, and pathology.
Download or read book Advanced and Metastatic Renal Cell Carcinoma an Issue of Urologic Clinics Volume 47 3 written by William C. Huang and published by Elsevier. This book was released on 2020-08-30 with total page 240 pages. Available in PDF, EPUB and Kindle. Book excerpt: The guest editors, Dr. William Huang and Dr. Ezequiel Becher, have assembled a state-of-the art issue devoted to Advanced and Metastatic Renal Cell Carcinoma (RCC). They have secured expert authors to contribute clinical reviews on the important topics involving treating and managing patients with RCC. Specific articles are devoted to the following topics: Imaging for Metastatic RCC; Adjuvant Therapy for Localized High Risk RCC; Current Standards for Therapeutic Sequencing for Advanced RCC; Role of Lymphadenectomy in patients with advanced RCC; Cytoreductive Nephrectomy in the Era of TKI/IO - Who, When and Why; Minimally Invasive Surgery for Patients with Locally Advanced and Metastatic Disease RCC; Evolving Role of Urologists in the Management of Advanced RCC; Neoadjuvant Therapy for Locally Advanced RCC; Epidemiology and Risk Assessment/Biomarkers for Patients with Advanced RCC; Radiation Therapy for Patients with Metastatic RCC; Evolving Role of Metastatectomy for Patients with Metastatic RCC; and Management of Non-Clear Cell Metastatic RCC. Readers will come away with the information they need to treat and manage patients and to improve outcomes.
Download or read book Sequential Use of Targeted Therapies TT in Metastatic Renal Cell Cancer mRCC Overall Results of a Large Experience written by G. Procopio and published by . This book was released on 2012 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt: Sequential Use of Targeted Therapies (TT) in Metastatic Renal Cell Cancer (mRCC): Overall Results of a Large Experience.
Download or read book Kidney Cancer written by Primo N. Lara and published by Springer. This book was released on 2015-06-10 with total page 400 pages. Available in PDF, EPUB and Kindle. Book excerpt: Kidney Cancer: Principles and Practice is a comprehensive and interdisciplinary textbook that encompasses all clinically relevant aspects of the disease. This new edition has been extensively updated and includes brand new material covering the most recent developments in kidney cancer diagnosis and therapy. The user-friendly and clinically oriented content of the book guarantees that it will be of great interest to a wide range of medical professionals, and every effort has been made to ensure that contributions are both easy to understand and directly related to patient care. Content presentation departs from the usual dense chapter format featuring a lengthy series of paragraphs. Instead, each chapter contains several boxed sections, including one that summarizes essential "take home points" for the busy clinician and another that presents a patient-oriented case highlighting the clinical application of elements discussed in that chapter. In addition, accessible original images, illustrations, and diagrams (some in full color) are used to simplify particularly complex material. This book will be of value for clinicians, researchers, residents, fellows, students, and knowledgeable lay people. The contributors comprise an international group of authors with expertise in kidney cancer epidemiology, molecular biology, pathology, diagnosis, clinical features, staging, prognostic and predictive factors, surgery, systemic therapy, and emerging investigational approaches, among others.
Download or read book Tivozanib Versus Sorafenib as Initial Targeted Therapy for Patients with Metastatic Renal Cell Carcinoma written by Robert J. Motzer and published by . This book was released on 2018 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Economic Burden of Renal Cell Carcinoma RCC and Treatment Patterns Overall Survival and Healthcare Costs Among Older Metastatic RCC Patients written by Hrishikesh Pradip Kale and published by . This book was released on 2018 with total page 123 pages. Available in PDF, EPUB and Kindle. Book excerpt: Background Renal cell carcinoma (RCC) is the most common type of kidney cancer. Patients diagnosed with metastatic RCC (mRCC) have shorter overall survival compared to those diagnosed at earlier stages. Several targeted therapies, which cost from $7,000 - $16,000 per month have been approved since 2005 to treat mRCC. In addition, there is a growing interest in the use of cytoreductive nephrectomy (CN) with targeted therapies among mRCC patients. However, little is known regarding the economic burden of RCC and role of CN and prescribing patterns of targeted therapies among older mRCC patients. Objectives 1) To assess the economic burden of RCC among older adults in the targeted therapy era 2) To compare the overall survival (OS) and total healthcare cost (THC) among older mRCC patients receiving CN and targeted therapy versus patients receiving targeted therapy alone 3) To describe prescribing patterns of targeted therapies and associated OS and THC among older mRCC patients. Methods This dissertation was conducted using the Surveillance Epidemiology and End Results (SEER) - Medicare linked data. For the first objective, the study included a prevalent cohort of RCC patients from 2013, diagnosed during 2005 - 2013 and continuously enrolled in Medicare. RCC patients were matched to non-cancer beneficiaries using propensity score matching. Generalized linear models estimated the incremental healthcare costs. Incremental total healthcare cost (THC) was multiplied by the estimated number of RCC patients on Medicare to calculate the total economic burden of RCC. For the second objective, we included patients diagnosed with mRCC between 2007-2014 and compared overall survival (OS), and THC between patients who received CN + targeted therapy and targeted therapy alone. A propensity score based inverse probability of treatment weighting (IPTW) method was used to balance the two treatment groups. A Cox proportional hazard model assessed the risk for death and a GLM compared healthcare costs between the groups. For the third objective, patients with mRCC were defined as patients who were diagnosed at stage-IV or at earlier stages but were currently using targeted therapies. Further, we restricted our sample to patients who initiated targeted therapy. We described the frequencies of the most common first and second line targeted therapies. We also described OS and THC per month for clear-cell and non-clear cell mRCC for each therapy and line of therapy. Results The first study included 10,392 each of RCC and control patients. The average THC associated with RCC was $7,419. The average THC was $4,584 for patients diagnosed at stage-I, $4,727 for stage-II, $9,331 for stage-III, and $31,637 for stage-IV. The annual economic burden of RCC on Medicare was estimated to be $1.5 billion. The second study included 471 mRCC patients that received CN + targeted therapy or targeted therapy alone. The median OS from the adjusted survival curves was significantly higher (p Conclusions The economic burden of RCC varied substantially between early stage and metastatic patients. Among mRCC patients, use of CN among targeted therapy users was associated with a higher median OS and similar monthly THC over a lifetime. Sunitinib and everolimus were the most common first and second line targeted therapies among mRCC patients. The descriptive analysis suggested that OS and THC were similar across types of targeted therapy sequences.
Download or read book Holland Frei Cancer Medicine written by Robert C. Bast, Jr. and published by John Wiley & Sons. This book was released on 2017-03-10 with total page 2004 pages. Available in PDF, EPUB and Kindle. Book excerpt: Holland-Frei Cancer Medicine, Ninth Edition, offers a balanced view of the most current knowledge of cancer science and clinical oncology practice. This all-new edition is the consummate reference source for medical oncologists, radiation oncologists, internists, surgical oncologists, and others who treat cancer patients. A translational perspective throughout, integrating cancer biology with cancer management providing an in depth understanding of the disease An emphasis on multidisciplinary, research-driven patient care to improve outcomes and optimal use of all appropriate therapies Cutting-edge coverage of personalized cancer care, including molecular diagnostics and therapeutics Concise, readable, clinically relevant text with algorithms, guidelines and insight into the use of both conventional and novel drugs Includes free access to the Wiley Digital Edition providing search across the book, the full reference list with web links, illustrations and photographs, and post-publication updates
Download or read book WHO Classification of Tumours of the Urinary System and Male Genital Organs written by International Agency for Research on Cancer and published by . This book was released on 2016-02-02 with total page 400 pages. Available in PDF, EPUB and Kindle. Book excerpt: WHO Classification of Tumours of the Urinary System and Male Genital Organs is the eighth volume in the 4th Edition of the WHO series on histological and genetic typing of human tumours. This authoritative, concise reference book provides an international standard for oncologists and pathologists and will serve as an indispensable guide for use in the design of studies monitoring response to therapy and clinical outcome. Diagnostic criteria, pathological features, and associated genetic alterations are described in a strictly disease-oriented manner. Sections on all recognized neoplasms and their variants include new ICD-O codes, epidemiology, clinical features, macroscopy, pathology, genetics, and prognosis and predictive factors. It contains numerous color photographs, MRIs, ultrasound images, CT scans, charts and references.
Download or read book Network Meta Analysis for Decision Making written by Sofia Dias and published by John Wiley & Sons. This book was released on 2018-03-19 with total page 484 pages. Available in PDF, EPUB and Kindle. Book excerpt: A practical guide to network meta-analysis with examples and code In the evaluation of healthcare, rigorous methods of quantitative assessment are necessary to establish which interventions are effective and cost-effective. Often a single study will not provide the answers and it is desirable to synthesise evidence from multiple sources, usually randomised controlled trials. This book takes an approach to evidence synthesis that is specifically intended for decision making when there are two or more treatment alternatives being evaluated, and assumes that the purpose of every synthesis is to answer the question "for this pre-identified population of patients, which treatment is 'best'?" A comprehensive, coherent framework for network meta-analysis (mixed treatment comparisons) is adopted and estimated using Bayesian Markov Chain Monte Carlo methods implemented in the freely available software WinBUGS. Each chapter contains worked examples, exercises, solutions and code that may be adapted by readers to apply to their own analyses. This book can be used as an introduction to evidence synthesis and network meta-analysis, its key properties and policy implications. Examples and advanced methods are also presented for the more experienced reader. Methods used throughout this book can be applied consistently: model critique and checking for evidence consistency are emphasised. Methods are based on technical support documents produced for NICE Decision Support Unit, which support the NICE Methods of Technology Appraisal. Code presented is also the basis for the code used by the ISPOR Task Force on Indirect Comparisons. Includes extensive carefully worked examples, with thorough explanations of how to set out data for use in WinBUGS and how to interpret the output. Network Meta-Analysis for Decision Making will be of interest to decision makers, medical statisticians, health economists, and anyone involved in Health Technology Assessment including the pharmaceutical industry.
